Core Financial Performance - For full-year 2025, Butterfly reported total revenue of $97.6 million, up 19% from 2024, driven by growth in the core point-of-care ultrasound (POCUS) business and Butterfly Embedded [1] - Fourth-quarter revenue totaled $31.5 million, up 41% year-over-year, marking the first quarter in company history to generate positive operating cash flow [2][3] - Adjusted EBITDA loss narrowed to $3.2 million in Q4 from a $9.1 million loss a year earlier, and for full-year 2025, adjusted EBITDA loss was $26.5 million, improving from $38.9 million in 2024 [7] Growth Drivers - Growth in Butterfly Embedded was primarily attributed to the execution of the $74 million Midjourney contract, which contributed $6.8 million of Q4 revenue [5][11] - The core POCUS business saw a revenue increase of 15% year-over-year, building on a 35% growth in the prior-year fourth quarter [13] - The launch of Compass AI in Q4 was noted as a tailwind for enterprise adoption, driving over 50% growth in the enterprise pipeline since its launch [14] Future Guidance - For full-year 2026, Butterfly forecasts revenue of $117–121 million, representing approximately 20–24% growth, with an adjusted EBITDA loss of $21–25 million [4][18] - The company expects Q1 2026 revenue of $24 million to $28 million, citing seasonality, and an adjusted EBITDA loss of $8 million to $10 million [17] Strategic Initiatives - Butterfly's strategic growth plan focuses on accelerating its core POCUS business, expanding into new care settings, and extending its semiconductor ultrasound platform [8] - The company has consolidated its semiconductor platform strategy under "Butterfly Embedded," moving away from the previous "Octave" branding [12] - Butterfly aims to reach a first commercial agreement in home care in the first half of 2026, with potential revenue opportunities of $40 million to $50 million [21] Market Expansion - Management sees meaningful opportunities in 2026 as it opens markets in South America and expands across the Middle East and Asia [15] - The company has surpassed 1,000 NGO partners worldwide, indicating a strong international presence [15]

Core Insights - Butterfly Network, Inc. (BFLY) reported a third-quarter 2025 loss of $0.13 per share, which was wider than the Zacks Consensus Estimate of a loss of $0.07 per share, and compared to a loss of $0.08 per share in the same period last year [1][9] - Revenues for the third quarter reached $21.5 million, reflecting a year-over-year increase of 4.5% and exceeding the Zacks Consensus Estimate by 2.4% [1][9] Revenue Performance - International revenues increased by 4% year over year to $5.4 million, attributed to the higher price point of the iQ3 probe launched internationally in Q3 2024 [2] - The overall revenue growth indicates a positive trend despite the wider loss reported [6] Margin Performance - The company's gross loss for the third quarter was $3.8 million, a significant decline from a gross profit of $12.2 million in the same quarter last year, primarily due to a 203.2% increase in the cost of revenues [3] Expense Analysis - Selling and marketing expenses rose by 10.6% year over year to $10.6 million, while research and development expenses decreased by 1.6% to $8.7 million. General and administrative expenses saw a slight drop of 0.7% to $9 million [4] - The operating loss for the quarter was $32.3 million, compared to a loss of $15.6 million in the same period of 2024 [4] Future Guidance - For 2025, the company anticipates revenues between $91 million and $95 million, indicating approximately 13% growth, with the Zacks Consensus Estimate currently at $91 million [5] - The adjusted EBITDA loss is expected to be between $32 million and $35 million, a slight adjustment from the previous estimate of $32 million to $37 million [5] Innovations and Developments - Recent innovations include the launch of an AI-powered Gestational Age Calculator in Malawi and Uganda, which is pending FDA review [6] - The HeartFocus by DESKi app became the first FDA-cleared third-party app on Butterfly Garden, enabling AI-guided echo exams [7] - The company has completed the development of the P5.1 chip and initiated the development of the sixth-generation Apollo AI chip for enhanced edge AI capabilities [7]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $21.5 million, reflecting a 5% growth over the prior year, driven by higher average selling prices and increased volume, particularly in the U.S. [14][15] - Gross margin, including a non-cash inventory write-off of $17.4 million, was negative 17.5%, compared to 59.5% in the prior year. Adjusted gross margin increased to 63.9% from 60% in the prior year [17][18] - Adjusted EBITDA loss was $8.1 million, an improvement from a loss of $8.4 million in Q3 2024, leading to a normalized cash burn of $3.9 million [18][19] - Cash and cash equivalents at the end of the quarter were $148 million, with a trailing 12-month cash use of $31.5 million [19] Business Line Data and Key Metrics Changes - Product revenue was $14.6 million, an increase of 8% versus Q3 2024, driven by higher average selling prices in international markets and increased volume in e-commerce and veterinary channels [15][16] - Software and other services revenue was $6.9 million, flat compared to the prior year, with increased licensing and services revenue offset by lower renewals of individual subscriptions [16] Market Data and Key Metrics Changes - Total international revenue increased 4% over the prior year to $5.4 million, primarily driven by price increases following the international launch of iQ3 [15] - U.S. revenue was $16.1 million, slightly up from the previous year, attributed to e-commerce sales and improved performance in the veterinary distribution channel [15] Company Strategy and Development Direction - The company is focusing on enterprise sales by building a strategy that integrates Butterfly more holistically within health systems, despite facing headwinds in the second quarter [5][6] - The five-year plan introduced multiple growth pillars, including deeper engagement in core business areas and expansion into new markets [5][6] - The AI strategy is seen as a significant accelerator, with successful trials demonstrating the economic impact of Butterfly's AI tools on patient care and hospital efficiency [8][12] Management's Comments on Operating Environment and Future Outlook - Management noted that while Q3 is typically the quietest quarter, they are optimistic about returning to momentum in 2026, with increased pipeline opportunities [5][21] - The company reaffirmed its full-year revenue guidance of $91 to $95 million, indicating a need to close larger deals in the pipeline to reach the higher end of the range [22][23] - Management expressed confidence in the long-term positioning of Butterfly Network, emphasizing the affordability and flexibility of their technology compared to traditional ultrasound solutions [24] Other Important Information - The company has strengthened its information security posture with new certifications, enhancing its competitive advantage in the market [7][56] - The P5.1 chip development has been completed, expected to significantly enhance imaging capabilities and performance, with production set to begin [26][27] Q&A Session Summary Question: Can you quantify the size of some deals that have been pushed due to macro factors? - Management indicated that deals can range from 100 to 200 probes, with large medical school deals also in the pipeline [33][35] Question: What is the outlook for the sales pipeline heading into 2026? - Management noted that while the time to close has extended, there are more deals stacking up, and they expect a lift in 2026 as budgets reset [41][42] Question: How will the cost-effectiveness data from the Rutgers study impact future sales? - The study establishes significant economic benefits, which will strengthen the company's position in enterprise sales discussions [43][46] Question: What is the status of the HomeCare program? - Management remains optimistic about the channel but emphasized that until agreements are finalized, nothing is certain [47] Question: What is needed to de-risk the launch of the P5.1 chip? - Management expressed confidence in the low risk of execution for the new product launch, citing successful past launches as a precedent [50][52] Question: How does the new information security certification help win business? - The company believes its cloud connectivity and security posture provide a competitive advantage, especially as the industry shifts towards cloud solutions [56][57]